The CCND1 G870A Gene Polymorphism and Brain Tumor Risk: a Meta-analysis

Background: In recent years, numerous studies have been performed to investigate the CCND1 G870Agene polymorphism impact on brain tumors susceptibility. Unfortunately, the results of previous studies were inconsistent. Therefore, we performed a meta-analysis to derive a more precise estimation of any association. Materials and Methods: We conducted a search in PubMed, Embase and CNKI covering all published papers up to November, 2013. Odds ratios (ORs) and their 95% confidence intervals (95% CIs) were applied to assess associations. Results: A total of 6 publications including 9 case-control studies met the inclusion criteria. The pooled ORs for the total included studies showed significant association among comparison A vs G (OR= 1.246, 95% CI= 1.092-1.423, p= 0.001), homozygote comparison AA vs GG (OR= 1.566, 95% CI= 1.194-2.054, p= 0.001), heterozygote comparison AG vs GG (OR= 1.290, 95% CI= 0.934-1.782, p= 0.122), dominant model AA/GA vs GG (OR= 1.381, 95% CI= 1.048-1.821, p= 0.022) and recessive model AA vs GA/GG (OR= 1.323, 95% CI= 1.057-1.657, p= 0.015) especially in glioma. Conclusions: CCND1 G870A polymorphism may increase brain tumor risk, especially for gliomas. However, more primary large scale and well-designed studies are still required to evaluate the interaction of CCND1 G870A polymorphism with brain tumor risk.